California is currently home to 5930 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Los Angeles, San Francisco, San Diego and Sacramento. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
This is a parallel, Phase 2, 2-arm study to evaluate the efficacy, safety, PK, and biological effects of SAR444656 compared with placebo in adult participants with moderate to severe HS aged ≥18 to 70 years. Study details include: Screening period: up to 4 weeks (30 days) Treatment duration: up to 16 weeks Follow-up period: up to 4 weeks Total study duration: up to 24 weeks Number of visits: 14
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2024
Locations: First OC Dermatology Site Number: 8400007, Fountain Valley, California
Conditions: Hidradenitis Suppurativa
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Recruiting
This study will evaluate the safety and efficacy of AT-1501 compared with tacrolimus in patients undergoing kidney transplantation.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
06/19/2024
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Kidney Transplant Rejection
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Recruiting
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: City of Hope National Medical Center, Duarte, California
Conditions: MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
Recruiting
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions.
Gender:
All
Ages:
Between 18 years and 130 years
Trial Updated:
06/19/2024
Locations: Research Site, Bakersfield, California
Conditions: Renal Disease
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: UCLA Hematology/Oncology - Westwood (Building 100) ( Site 1918), Los Angeles, California
Conditions: Melanoma
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Recruiting
The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/19/2024
Locations: Cancer and Blood Specialty Clinic, Long Beach, California
Conditions: Melanoma
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
Recruiting
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California
Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Carcinoma
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
Recruiting
This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: Kern Research Inc, Bakersfield, California
Conditions: Atopic Dermatitis
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Valley Clinical Trials, Inc., Covina, California
Conditions: Obesity, Cardiovascular Diseases
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimi... Read More
Gender:
Male
Ages:
All
Trial Updated:
06/19/2024
Locations: Beckman Research Institute of the City of Hope, Duarte, California
Conditions: Prostate Adenocarcinoma
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
Recruiting
BBI-355 is an oral, potent, selective checkpoint kinase 1 (or CHK1) small molecule inhibitor in development as an ecDNA (extrachromosomal DNA) directed therapy (ecDTx). This is a first-in-human, open-label, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-355 administered as a single agent or in combination with select therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Sarcoma Oncology, Santa Monica, California
Conditions: Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma